Cargando…
Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis
BACKGROUND: Post-acute coronavirus 2019 (COVID-19) syndrome is now recognized as a complex systemic disease that is associated with substantial morbidity. OBJECTIVES: To estimate the prevalence of persistent symptoms and signs at least 12 weeks after acute COVID-19 at different follow-up periods. DA...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812092/ https://www.ncbi.nlm.nih.gov/pubmed/35124265 http://dx.doi.org/10.1016/j.cmi.2022.01.014 |
_version_ | 1784644574556192768 |
---|---|
author | Alkodaymi, Mohamad Salim Omrani, Osama Ali Fawzy, Nader A. Shaar, Bader Abou Almamlouk, Raghed Riaz, Muhammad Obeidat, Mustafa Obeidat, Yasin Gerberi, Dana Taha, Rand M. Kashour, Zakaria Kashour, Tarek Berbari, Elie F. Alkattan, Khaled Tleyjeh, Imad M. |
author_facet | Alkodaymi, Mohamad Salim Omrani, Osama Ali Fawzy, Nader A. Shaar, Bader Abou Almamlouk, Raghed Riaz, Muhammad Obeidat, Mustafa Obeidat, Yasin Gerberi, Dana Taha, Rand M. Kashour, Zakaria Kashour, Tarek Berbari, Elie F. Alkattan, Khaled Tleyjeh, Imad M. |
author_sort | Alkodaymi, Mohamad Salim |
collection | PubMed |
description | BACKGROUND: Post-acute coronavirus 2019 (COVID-19) syndrome is now recognized as a complex systemic disease that is associated with substantial morbidity. OBJECTIVES: To estimate the prevalence of persistent symptoms and signs at least 12 weeks after acute COVID-19 at different follow-up periods. DATA SOURCES: Searches were conducted up to October 2021 in Ovid Embase, Ovid Medline, and PubMed. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS AND INTERVENTIONS: Articles in English that reported the prevalence of persistent symptoms among individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection and included at least 50 patients with a follow-up of at least 12 weeks after acute illness. METHODS: Random-effect meta-analysis was performed to produce a pooled prevalence for each symptom at four different follow-up time intervals. Between-study heterogeneity was evaluated using the I2 statistic and was explored via meta-regression, considering several a priori study-level variables. Risk of bias was assessed using the Joanna Briggs Institute tool and the Newcastle-Ottawa Scale for prevalence studies and comparative studies, respectively. RESULTS: After screening 3209 studies, a total of 63 studies were eligible, with a total COVID-19 population of 257 348. The most commonly reported symptoms were fatigue, dyspnea, sleep disorder, and difficulty concentrating (32%, 25%, 24%, and 22%, respectively, at 3- to <6-month follow-up); effort intolerance, fatigue, sleep disorder, and dyspnea (45%, 36%, 29%, and 25%, respectively, at 6- to <9-month follow-up); fatigue (37%) and dyspnea (21%) at 9 to <12 months; and fatigue, dyspnea, sleep disorder, and myalgia (41%, 31%, 30%, and 22%, respectively, at >12-month follow-up). There was substantial between-study heterogeneity for all reported symptom prevalences. Meta-regressions identified statistically significant effect modifiers: world region, male sex, diabetes mellitus, disease severity, and overall study quality score. Five of six studies including a comparator group consisting of COVID-19–negative cases observed significant adjusted associations between COVID-19 and several long-term symptoms. CONCLUSIONS: This systematic review found that a large proportion of patients experience post-acute COVID-19 syndrome 3 to 12 months after recovery from the acute phase of COVID-19. However, available studies of post-acute COVID-19 syndrome are highly heterogeneous. Future studies need to have appropriate comparator groups, standardized symptom definitions and measurements, and longer follow-up. |
format | Online Article Text |
id | pubmed-8812092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88120922022-02-04 Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis Alkodaymi, Mohamad Salim Omrani, Osama Ali Fawzy, Nader A. Shaar, Bader Abou Almamlouk, Raghed Riaz, Muhammad Obeidat, Mustafa Obeidat, Yasin Gerberi, Dana Taha, Rand M. Kashour, Zakaria Kashour, Tarek Berbari, Elie F. Alkattan, Khaled Tleyjeh, Imad M. Clin Microbiol Infect Systematic Review BACKGROUND: Post-acute coronavirus 2019 (COVID-19) syndrome is now recognized as a complex systemic disease that is associated with substantial morbidity. OBJECTIVES: To estimate the prevalence of persistent symptoms and signs at least 12 weeks after acute COVID-19 at different follow-up periods. DATA SOURCES: Searches were conducted up to October 2021 in Ovid Embase, Ovid Medline, and PubMed. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS AND INTERVENTIONS: Articles in English that reported the prevalence of persistent symptoms among individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection and included at least 50 patients with a follow-up of at least 12 weeks after acute illness. METHODS: Random-effect meta-analysis was performed to produce a pooled prevalence for each symptom at four different follow-up time intervals. Between-study heterogeneity was evaluated using the I2 statistic and was explored via meta-regression, considering several a priori study-level variables. Risk of bias was assessed using the Joanna Briggs Institute tool and the Newcastle-Ottawa Scale for prevalence studies and comparative studies, respectively. RESULTS: After screening 3209 studies, a total of 63 studies were eligible, with a total COVID-19 population of 257 348. The most commonly reported symptoms were fatigue, dyspnea, sleep disorder, and difficulty concentrating (32%, 25%, 24%, and 22%, respectively, at 3- to <6-month follow-up); effort intolerance, fatigue, sleep disorder, and dyspnea (45%, 36%, 29%, and 25%, respectively, at 6- to <9-month follow-up); fatigue (37%) and dyspnea (21%) at 9 to <12 months; and fatigue, dyspnea, sleep disorder, and myalgia (41%, 31%, 30%, and 22%, respectively, at >12-month follow-up). There was substantial between-study heterogeneity for all reported symptom prevalences. Meta-regressions identified statistically significant effect modifiers: world region, male sex, diabetes mellitus, disease severity, and overall study quality score. Five of six studies including a comparator group consisting of COVID-19–negative cases observed significant adjusted associations between COVID-19 and several long-term symptoms. CONCLUSIONS: This systematic review found that a large proportion of patients experience post-acute COVID-19 syndrome 3 to 12 months after recovery from the acute phase of COVID-19. However, available studies of post-acute COVID-19 syndrome are highly heterogeneous. Future studies need to have appropriate comparator groups, standardized symptom definitions and measurements, and longer follow-up. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-05 2022-02-03 /pmc/articles/PMC8812092/ /pubmed/35124265 http://dx.doi.org/10.1016/j.cmi.2022.01.014 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Systematic Review Alkodaymi, Mohamad Salim Omrani, Osama Ali Fawzy, Nader A. Shaar, Bader Abou Almamlouk, Raghed Riaz, Muhammad Obeidat, Mustafa Obeidat, Yasin Gerberi, Dana Taha, Rand M. Kashour, Zakaria Kashour, Tarek Berbari, Elie F. Alkattan, Khaled Tleyjeh, Imad M. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
title | Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
title_full | Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
title_fullStr | Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
title_full_unstemmed | Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
title_short | Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
title_sort | prevalence of post-acute covid-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812092/ https://www.ncbi.nlm.nih.gov/pubmed/35124265 http://dx.doi.org/10.1016/j.cmi.2022.01.014 |
work_keys_str_mv | AT alkodaymimohamadsalim prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT omraniosamaali prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT fawzynadera prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT shaarbaderabou prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT almamloukraghed prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT riazmuhammad prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT obeidatmustafa prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT obeidatyasin prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT gerberidana prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT taharandm prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT kashourzakaria prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT kashourtarek prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT berbarielief prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT alkattankhaled prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis AT tleyjehimadm prevalenceofpostacutecovid19syndromesymptomsatdifferentfollowupperiodsasystematicreviewandmetaanalysis |